THE THERAPEUTIC MANAGEMENT OF THE GIANT GASTRIC NEUROENDOCRINE TUMOR (NET) – CASE REPORT by Adrian MUREŞAN et al.
I NTRODUCTION Gastrointestinal tract neuroendocrine tumors (NET) 
are relatively rare neoplasms, diverted from the diffuse 
endocrine system (DES) and classified as apudoma 
(APUD). These neoplasms include pancreatic endo-
crine tumors and carcinoid tumors of the digestive tract. 
 
Although malign, the digestive NET have slow growth, but 
also metastatic potential. They represent a heterogeneous 
group of tumors, rare (approximately 1% of all malign tu-
mors), with a rate of incidence of 2-3/100.000 inhabitants/
year (1, 2). The digestive NET are classified depending on 
the location and dimension of the primary tumor, the tu-
mor grading, the markers of cell proliferation, the local and 
vascular invasiveness and the production of active biologi-
cal substances [3, 4]. 
 
The main types of digestive NET are: 
• Endocrine tumors well differentiated characterized by 
a low malign index, which are aggressive especially 
due to metastases presence 
• Endocrine carcinoma poorly differentiated with a high 
grade of malignity and a bad prognosis 
• Endocrine and exocrine mixed tumors 
 
Gastro-entero-pancreatic endocrine tumors can 
generate specific symptoms due to hormonal hy-
persecretion. The diagnosis is based on the clini-
cal arguments, the dosage of hormone, the imag-
istic methods of primary tumor and metastases 
detection as well as on the scintigraphic methods. 
The golden standard is the histological diagnosis 
which has to be obtain as many times as possible. 
The curative treatment is, obviously, the major 
objective, but such a treatment is rarely possible, 
because of the discovery in a late stage, 40%-70% of the 
patients already have liver metastases at the diagnosis time 
[5, 6]. The surgical treatment is the only curative one. Of-
ten, the patients come to the hospital as an emergency 
(occlusion, appendicular syndrome), and the histopathol-
ogy detects a neuroendocrine tumor; in such cases a radi-
cal intervention, within oncological limits is to be consid-
ered, for a loco-regional assessment. 
 
Chemotherapy brings benefits especially in poorly differ-
entiated forms, using schemes that associate etoposide and 
cisplatin [5]. 
 
Chemoembolization is used in unresectable NET for tumor 
mass reduction, with a symptomatic and survival improvement. 
The clinical cours of these patients is sometime imprevis-
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In Romania, about 1.3 million people suffer from a rare disease in their 
lifetime. Although a low prevalence in the population, rare diseases can be 
considered a public health priority, as their consequences are numerous and 
occur on many dimensions (diseases generating death, invalidity, high economic 
and social costs, etc.).   
Gastric neuroendocrine tumors (NET), mainly through their metastatic 
potential, is a type of tumors with unfavorable evolution. Because of their 
potential to increase their size and volum, the therapeutic approach of these forms 
is complex, phased and multi-disciplinary. The case we presented strengthens the 
necessity for using a multisectoral approach in case management of rare diseases, 
as neuroendocrin tumor is.  
The late presentation of the patient, with a tumor having significant 
dimensions, as well as the absence of other evocative symptoms of an secreting 
tumors derived from the diffuse endocrine system, requires an inter-disciplinary 
approach to solving the case with preoperative chemical embolization extremely 
useful for reducing tumor volume. 
Detection, diagnosis, treatment, monitoring and subsequent supervision of the 
case must be achieved through collaboration and active participation of a 
multidisciplinary medical team.  
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Factors associated with por prognosis 
Liver metastases 
Extent of liver metastases 
Lymph nodes metastases 
Bone metastases 
Development of ectopic Cushing’ syndrome 
Rapid tumor growth (in liver) 
Factors associated with aggressive clinical course and development of liver metastases 
Tumor size over 3 cm 
Female gender 
Absence of MEN1 syndrome 
Increases serum gastrine level 
Primary localization in pancreas 
Results of flow citometry (high S phase) 
We are presenting a gastric NET case, operated in our clinic. 
 
Clinical case – Giant gastric neuronedocrine tumor, operated in the 1st 
Surgery Clinic from Tg. Mureş 
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The case of a 46 years old patient, 
without other notable co-morbidities, 
was submitted in our service for dif-
fuse abdominal pain and increase in 
volume of the abdomen. 
 
The initial evaluation included the 
complete medical history and the 
physical examination by body sys-
tems. 
 
From the medical history we noted 
that the disease started in a insidious 
way, by graduated increase of the 
abdomen volume, followed by the 
appearance of a diffuse abdominal 
pain, unsystematized, unconditioned 
by food intake effort, position or by 
well established  timing. 
 
General clinical exam on admission 
revealed: moderate general condition, 
normal weight patient, hemodynamic 
and respiratory stable, apyretic, pale-
sallow teguments and mucosa, evok-
ing neoplastic impregnation. 
 
Local exam: mobile abdomen, mov-
ing with breathing, relaxed, asymmet-
rically increased in volume at epigas-
tric and left hypochondrium level, 
painful on superficial and profound 
palpation on epigastric and left hypo-
chondrium level, where is noted the 
presence of a tumor about 9 cm in 
diameter, mobile against the profound 
levels, imprecisely delimited, painful 
on palpation; intestinal transit is pre-
sent; good digestive tolerance. 
 
Laboratory investigations were within 
normal limits. 
 
CT scan reveals a space replacing 
process, localized in the left hypo-
chondrium, native and post contrast 
inhomogeneous, with a polilobate 
contour and the dimensions of 
109/130/189 mm. 
 
At 48 hours preoperative, after an 
interdisciplinary review af the case 
with the oncologist and the interven-
tional radiologist, has been estab-
lished the opportunity of a chemoem-
bolization of the left gastric artery 
with 400 mg of 5 FU, using a femoral  
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Figure 1. Highlighting arteriography of the left gastric artery; arterial 
branches irrigates the tumor 
Figure 2. The embolization of the left gastric artery 
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macroscopic aspect. Total gastrec-
tomy with terminal-lateral esophago-
jejuno anastomosis on omega loop 
with Braun fistula has been performed 
(Figure 4). 
 
There were no special anesthetic 
problems registered, during the entire 
surgical intervention the patient was 
stable regarding the blood pressure. 
 
Postoperative evolution was favor-
able, with resumption of the transit on 
the third day postoperative, enteral 
nutrition started on day 7 and the pa-
tient was discharged after 12 days 
from the surgical intervention. 
 
The postoperative result of the histo-
pathological examination from the 
resection piece showed a gastric neu-
roendocrine carcinoma with a high 
grade of malignity which infiltrates 
the entire gastric wall, with the se-
rosal invasion and tear and produces 
metastasis in 1 of 11 lymph nodes of 
the greater curvature and in 1 of 6 
lymph nodes of the lesser curvature. 
 
After the definitive histopathological 
result the patient was send to oncol-
ogy for chemotherapy. 
 
At present time, after 2 months from 
surgery, the patient presents a good 
general condition and will undergo 
control endoscopy and computer to-
mography (Figure 5, 6, 7 8, 9). 
 
 
D ISCUSSIONS The presented case was a rare 
pathology. It is a neoplastic disease 
having a starting point the cells of 
diffuse endocrine system (DES). 
 
Neuroendocrine tumors can be spo-
radic or in multiple endocrine neo-
plasia syndromes (MEN I); the risk 
of a person with a 1st degree relative 
suffering from a neuroendocrine tu-
mor is 4 times greater than general 
population.; a recent populational 
study showed that about 20% of 
those with NET will develop another 
neoplasm, more frequent  a digestive 
one. 
approach with the complete obstruction of the left gastric artery using Ta-
chocomb pellets, arteriographicaly objectified, for the purpose of tumor 
mass reduction and to facilitate the surgery  (Figure 1,2,3). 
 
Surgery is required practicing a left subcostal incision which reveals a giant 
gastric tumor which penetrates the pancreas, transverse mesocolon and the 
celiac trunk. The liver and the other abdominal organs presented normal 
Figure 3.  Final aspect postembolization 
Figure 4. The aspect of the surgical resection piece 
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metabolite is 5HIAA), histamine (its 
urinary metabolite is methylimida-
zole acetic acid), tachykinins, P sub-
stance, A neurokinin or K polypep-
tide, which are responsible for the 
flush and can be an early indicator 
of the carcinoid syndrome. 
 
Carcinoid syndrome usually appears 
late in the disease evolution, accom-
panied by the liver metastases, as a 
result of hormonal hyper secretion 
and is classically described as the 
association of flush and diarrhea. 
Less frequent, the patients can pre-
sent a pelagroid syndrome, wheez-
ing or palpitations (the cardiac and 
pulmonary disease usually appears 
after years of carcinoid syndrome 
evolution) [3, 7, 8]. 
 
Carcinoid crises characterized by an 
intense flush, bronchospasm, tachy-
cardia and blood pressure instability, 
is usually caused by the anesthetic 
drugs, intraoperative mobilization of 
the tumor or by other invasive pro-
cedures such as radiofrequency abla-
tion or chemoembolization. 
 
Pancreatic NET secrets one or more 
hormones, either those normally 
secreted by the endocrine pancreatic 
cells (insulin, glucagon, soma-
tostatin), or the non-pancreatic hor-
mones such as adrenocorticotropic 
hormone [9]. The most frequent pan-
creatic NET is represented by insuli-
noma. As a result of the insulin hy-
persecretion the patients presents 
hypoglycemic symptomatic episodes 
with dizziness, confusion, sight dis-
orders and even coma. The insulin 
and the C peptide determination 
confirm the diagnosis. The glucago-
noma is a glucagonoma secreting 
tumor with two main clinical mani-
festations: the presence of a migra-
tory necrosant rash and of the diabe-
tes mellitus (by glycogenolysis and 
hepatic gluconeogenesis hyper 
stimulation, in other words hyper-
glycemia), with an usually increased 
insulin level (the ketoacidosis occur-
rence is rare in these patients). The 
diagnosis is based on the glucagon 
determination, whose level is  
Carcinoid tumors can be localized anywhere at the digestive tract level,  
but more frequent they are found near ileocaecal valve. 
 
They can be asymptomatic or they can generate obstructive symptoms. The 
clinical symptoms are the expression of the hormonal hyper secretion. The 
substances released by a carcinoid tumor include: serotonin (its urinary 
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Figure 5. Gastric wall with gastric mucosa and underlying with tumoral for-
mation (neuroendocrine carcinoma) 
Figure 6. Tumoral cells present cytoplasmic positivity on Chromogranin im-
munomarking 
Figure 7. Tumoral cells present cytoplasmic positivity on Synaptophisin 
immunomarking 
Figure 8. Tumoral cells present cytoplasmic positivity on panCitokeratia 
immunomarking  
Figure 9.  Tumoral cells present nuclear positivity on Ki67 immu-
nomarking (increased proliferation rate) 
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increased, and by demonstration using imag-
istic methods of a pancreatic tumor [7, 10]. 
 
Somatostatinoma is usually confused with 
pancreatic adenocarcinoma. Clinically the 
patients present an obstructive jaundice, the 
tumors having large dimensions. The soma-
tostatinoma is associated with diabetes melli-
tus, diarrhea, steatorrhea and lithiasis caused 
by the biliary stasis. 
 
Gastrinoma (Zollinger-Ellison syndrome) pro-
duces multiple and recurrent ulcers, with frequent 
postbulbar localization, recurrent after surgery. 
The gastrinoma is associated with diarrhea and 
steatorrhea due to pancreatic enzymes inactiva-
tion by acid excess, and with esophagitis. The 
diagnosis is based on gastrine determination. 
 
VIPoma is a rare tumor that produces watery and 
profuse diarrhea and pronounced hypokalemia 
caused by hyper secretion of the vasoactive intes-
tinal peptide (VIP). The diagnosis is made by de-
termining the VIP and highlighting the tumor 
through imaging (hypervascular tumor) [5, 11]. 
 
At a patient with clinical suspicion of NET, 
according to the current recommendations, one 
must first determine chromogranine A and 
5HIAA and as a second line of tests, depending 
on the clinical suspicion: serum gastrine, insulin 
and C peptide, glucagon, VIP, somatostatin. 
 
Also, chromogranin A levels are increased in car-
cinoid tumors and can be used for disease progres-
sion [12, 13]. 
For tumor detection it is necessary a multimodal 
approach that includes: CT scan, MRI, endoscopy, 
echoendoscopy, somatostain receptors scintigra-
phy (the most sensitive method for metastases 
detection and tracking necrotic NET). 
 
The prognosis of these tumors differs, the litera-
ture agrees that prognosis concerning the local-
ization is the best for carcinoid tumors of the 
appendix, following in a decreasing order: rec-
tum, intestine and stomach. 
 
The case we presented had an immediate favorable 




C ONCLUSIONS The particularity is represented in this 
case by the late presentation of the patient, with 
a tumor having significant dimensions, as 
well as the absence of other evocative  32 
symptoms of an secreting tumors derived from the diffuse endocrine system. Also the particularity of this case is repre-
sented by the necessity of an interdisciplinary approach of the tumor with preoperative chemoembolization extremely use-
ful for the reduction of the tumoral volume. Another particularity was represented also by the surprising histopathological 
result. The case we presented strengthens the necessity for using a multisectoral approach in case management of rare dis-
eases, as neuroendocrin tumor is. Detection, diagnosis, treatment, monitoring and subsequent supervision of the case must 
be achieved through collaboration and active participation of a multidisciplinary medical team.  
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T he Latin Association for the Analysis of Healthcare Systems (ALASS) was created in January 1989, with the aim of contributing to issues in the healthcare systems within the Latin countries healthcare systems, through the sharing of experience and the acquisition of niw skills 
among healthcare professionals (doctors, managers, health economists etc.) and researchers from different countries with a common character-
istic, i.e. the Latin culture. This common culture is seen in the perception of the quality of life, the behaviour towards the prevention of dis-
eases and the utilisation of the healthcare services, despite concomitant national, regional and local peculiarities. ALASS has about 300 indi-
vidual members (majority of whom are from Europe) and 30 institutional members from 25 countries in different continents. Last year, 
ALASS organized, for the first time, a congress in Latin America (Mexico) with professionals from European, Northern and Southern Ameri-
can joining the local participants. “2010 was a year of new hopes for us”; the Mexico congress was an important step to get “closer to our vi-
sion which is to effectively be a Latin organization”, said Prof Anamaria Malik (Brasilia), president of the association at the press conference 
organized in that occasion. Romania has always been represented in ALASS, and organized an ALASS congress in Bucharest in 2004. The 
institutional members from Romania are the National School of Public Health and Health Services Management and the Romanian Associa-
tion of Public Health and Healthcare Management. Several Romanian individual members are regular participants in the ALASS scientific 
events dedicated to various themes of interest in the field of public health and healthcare management. 
Useful information on the advantage of becoming an ALASS member and on how to do it can be found on the website of the association 
(www.alass.org). Visiting the website regularly, detailed information can be found about the main scientific manifestations of the association, 
e.g.: the annual congress (CALASS) which lasts for three days the one day workshops organized each trimester and the summer school in 
management of health services (UDEASS), consisting of five courses lasting one week each. CALASS 2011 will focus on the governance in 
healthcare organizations and will be held in Lausanne (Switzerland) lasting from the 1st-3rd of September. The first two workshops  in 2011 
will be held in Italy: one focusing  on the networks in healthcare and will be held in Ancona, on the 27th of May, and the other focus ingon the 
assessment of doctors’ services and will be hold in Milan, on the 17th of June. The annual congress could be attended by any professionals 
who are interested. The number of participants for the workshops is limited (maximum 25-30). UDEASS 2011 will be hosted by the Univer-
sity of Luxembourg, from the 18th to the 22nd July. The proposed courses are: healthcare technologies assessment, tsocial marketing, human 
resource management, clonical pathways and qualitative research in healthcare.  The courses will be taught   in French (except the last one 
which will be in  Spanish and could be attended by maximum 20 participants per course (www.udeass.lu).  
Any professionals  who share the ALASS mission and vision, and believe that the scientific events of the  association could help them to cope 
with their day-to-day challenges in their professional activity, are warmly invited to contact us (email: alass@alass.org). 
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